Patrick Schöffski, MD, on Eribulin for Soft-Tissue Sarcomas
2015 ASCO Annual MeetingPatrick Schöffski, MD, of the University Hospital Leuven, discusses a phase III study in which he and his colleagues found, for the first time in soft-tissue sarcomas, a significant overall survival benefit of a single agent compared to a standard treatment (Abstract LBA10502).
Related Videos
Eduardo Cazap, MD, PhD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Latin American Perspective
Eduardo Cazap, MD, PhD, of the Latin American & Caribbean Society of Medical Oncology, and James O. Armitage, MD, of the University of Nebraska Medical Center,...
Andrew D. Seidman, MD, and Clifford A. Hudis, MD, on Breast Cancer Decision Analysis
Clifford A. Hudis, MD, and Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discuss the use of the decision support system Watson for Oncology and...
Richard G. Margolese, MD, Summarizes NSABP B-35 Trial Results for Postmenopausal Women With DCIS
Richard G. Margolese, MD, of McGill University discusses the improvement in breast cancer-free interval with anastrozole vs tamoxifen in patients with DCIS undergoing lumpectomy pl...
Claus Garbe, MD, Summarizes Results of the DECOG Trial on SLNB-Positive Melanoma
Claus Garbe, MD, of the University of Tuebingen, discusses the survival of sentinel lymph node biopsy–positive melanoma patients with and without complete lymph node dissection (
Gregory T. Armstrong, MD, MSCE, and Lisa Diller, MD, on Reduction of Late Mortality in Childhood Cancer Survivors
Lisa Diller, MD, of Dana-Farber Cancer Institute, and Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discuss the findings of a landmark ...
